Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
26.39
-0.41 (-1.55%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Forte Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -69.38 | -35.48 | -31.48 | -13.88 | -21.71 | |
| Depreciation & Amortization | 0.06 | 0.04 | 0.01 | - | 0.04 | |
| Asset Writedown & Restructuring Costs | - | - | - | - | 0.06 | |
| Loss (Gain) From Sale of Investments | -0.24 | -0.16 | -0.13 | - | - | |
| Stock-Based Compensation | 6.26 | 3.1 | 3.28 | 4.01 | 4.21 | |
| Change in Accounts Payable | 5.54 | 3.02 | 0.27 | 0.21 | -0.29 | |
| Change in Income Taxes | 1.04 | - | - | - | - | |
| Change in Other Net Operating Assets | 5.83 | -1.26 | -0.66 | 1.47 | 1.01 | |
| Operating Cash Flow | -50.88 | -30.75 | -28.71 | -8.19 | -16.68 | |
| Capital Expenditures | -0.12 | -0.04 | -0.09 | - | - | |
| Investment in Securities | 36.35 | -35.96 | 0.14 | - | - | |
| Investing Cash Flow | 36.23 | -35.99 | 0.05 | - | - | |
| Issuance of Common Stock | 76.83 | 53.01 | 25.02 | 7.24 | 0.06 | |
| Repurchase of Common Stock | -0.03 | -0.04 | -0.06 | - | - | |
| Other Financing Activities | -7.44 | -1.12 | -0.27 | - | -0.11 | |
| Financing Cash Flow | 69.36 | 51.86 | 24.68 | 7.24 | -0.04 | |
| Net Cash Flow | 54.71 | -14.88 | -3.98 | -0.94 | -16.72 | |
| Free Cash Flow | -51 | -30.78 | -28.79 | -8.19 | -16.68 | |
| Free Cash Flow Per Share | -3.46 | -10.56 | -22.80 | -11.77 | -29.85 | |
| Levered Free Cash Flow | -26.94 | -16.14 | -17.4 | -3.18 | -9.02 | |
| Unlevered Free Cash Flow | -26.94 | -16.14 | -17.4 | -3.18 | -9.02 | |
| Change in Working Capital | 12.41 | 1.76 | -0.39 | 1.68 | 0.72 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.